...
首页> 外文期刊>Biochemical and Biophysical Research Communications >Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones
【24h】

Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones

机译:氯原酯酶的抑制和分子建模研究对氯吡啶基 - 噻吩基和2-吡唑啉衍生物的抑制作用

获取原文
获取原文并翻译 | 示例
           

摘要

Super-activation of cholinesterases (acetylcholinesterase and butyrylcholinesterase) are linked to various neurological problems most precisely Alzheimer's disease (AD), which leads to senile dementia. Therefore, cholinesterases (AChE & BChE) inhibition are considered as a promising strategy for the treatment of Alzheimer's disease. FDA approved drugs for the treatment of AD, belong to a group of cholinesterase inhibitors. However, none of them is able to combat or completely abrogate the disease progression. Herein, we report a series of newly synthesized chalcone derivatives with anti-AD potential. For this purpose, a series of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones were tested for their cholinesterases (AChE & BChE) inhibitory activity. All compounds were found as selective inhibitor of AChE. In piperidyl chalcones derivatives compound 1e having IC50, of 0.16 +/- 0.008 mu M and 2m in 2-pyrazoline chalcones with IC50 of 0.13 +/- 0.006 mu M, were found to be the most potent inhibitors of AChE, exhibiting approximate to 142 and approximate to 173-fold greater inhibitory potential compared to the reference inhibitor i.e., Neostigmine (IC50 SEM = 22.2 +/- 3.2 mu M). Molecular docking studies of most potent inhibitors were carried out to investigate the binding interactions inside the active site. Molecular docking study revealed that potent compounds and co-crystalized ligand had same binding orientation within the active site of target enzyme. Most of these compounds are selective inhibitors of AChE with a potential use against progressive neurodegenerative disorder and age related problems. (C) 2016 Elsevier Inc. All rights reserved.
机译:胆碱酯酶的超活化(乙酰胆碱酯酶和丁酰胆碱酯酶)与各种神经病学问题相连,最精确的阿尔茨海默病(AD),其导致老年痴呆。因此,胆碱酯酶(ACHE和BCHE)抑制被认为是治疗阿尔茨海默病的有希望的策略。 FDA批准用于治疗广告的药物,属于一组胆碱酯酶抑制剂。然而,他们都没有能够打击或完全消除疾病的进展。在此,我们报告了一系列具有抗AD潜力的新合成的螯合衍生物。为此目的,测试一系列哌啶基 - 噻吩基和2-吡唑啉衍生物的Chalcones的胆碱酯酶(ACHE&BCHE)抑制活性。将所有化合物作为疼痛的选择性抑制剂。在具有0.13 +/-0.006μm的2-吡唑啉chalces中具有0.16 +/-0.008μm和2m的哌啶基Chalcones衍生物1e,含有0.13 +/-0.006μm的2-吡唑啉chalcones,是最有效的疼痛抑制剂,表现为142与参考抑制剂IE,Neostigmine(IC50 SEM = 22.2 +/-3.2μm)相比,近似为173倍的抑制潜力。进行了大多有效抑制剂的分子对接研究,以研究活性位点内的结合相互作用。分子对接研究表明,有效的化合物和共结晶配体在靶酶的活性位点内具有相同的结合取向。大多数这些化合物是疼痛的选择性抑制剂,其潜在使用免受渐进神经变性疾病和年龄相关问题。 (c)2016年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号